Literature DB >> 2529965

Changes of the degree of hypertrophy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment.

J M Curtius1, J Stoecker, B Loesse, R Welslau, D Scholz.   

Abstract

The aim of our study was to establish the extent to which therapy of hypertrophic obstructive cardiomyopathy (HOCM) can influence the degree of hypertrophy. By means of two-dimensionally guided M-mode echocardiography, 120 patients with HOCM (age range 4-72 years, mean age 41 years) were observed over an average period of 49 +/- 41 months. Depending on the respective therapy, we formed four patient groups: group 1: 13 patients without any therapy (follow-up period 31 +/- 30 months); group 2: 27 patients receiving propranolol (follow-up period 47 +/- 34 months); group 3: 50 patients receiving verapamil (follow-up period 39 +/- 27 months), and group 4: 30 patients with myectomy (follow-up period 34 +/- 32 months). In group 4, as expected, the thickness of the interventricular septum (IVS) decreased postoperatively (from 24.2 +/- 4.5 to 19.8 +/- 6.7 mm, p less than 0.05), and the left ventricular posterior wall (LVPW) thickness also decreased later postoperatively (from 13.0 +/- 2.6 to 11.9 +/- 2.3 mm, p less than 0.05). The left ventricular diameters increased. In groups 2 and 3 treated with pharmacotherapy as in the untreated patients of group 1, on average there was no change in IVS and LVPW thickness nor in the left ventricular diameters (with the exception of increasing left ventricular end-diastolic diameter in the propranolol-treated group). In contrast to group 1, in occasional cases there were substantial decreases of IVS thickness (11% of the patients in group 2, 13% in group 3) or LVPW thickness (13% of the patients in group 2, 12% in group 3).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2529965     DOI: 10.1159/000174501

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  3 in total

Review 1.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.

Authors:  H Seggewiss
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

2.  Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss; A Rigopoulos; D Welge; P Ziemssen; L Faber
Journal:  Clin Res Cardiol       Date:  2007-09-27       Impact factor: 5.460

3.  Medical therapy versus interventional therapy in hypertropic obstructive cardiomyopathy.

Authors:  Hubert Seggewiss
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.